GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Galapagos NV (OTCPK:GLPGF) » Definitions » EV-to-EBIT

Galapagos NV (Galapagos NV) EV-to-EBIT

: -297.44 (As of Today)
View and export this data going back to 2005. Start your Free Trial

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Galapagos NV's Enterprise Value is $-2,005.0 Mil. Galapagos NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $6.7 Mil. Therefore, Galapagos NV's EV-to-EBIT for today is -297.44.

The historical rank and industry rank for Galapagos NV's EV-to-EBIT or its related term are showing as below:

GLPGF' s EV-to-EBIT Range Over the Past 10 Years
Min: -852.63   Med: -19.78   Max: 73.23
Current: -254.74

During the past 13 years, the highest EV-to-EBIT of Galapagos NV was 73.23. The lowest was -852.63. And the median was -19.78.

GLPGF's EV-to-EBIT is ranked better than
99.77% of 443 companies
in the Biotechnology industry
Industry Median: 8.24 vs GLPGF: -254.74

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Galapagos NV's Enterprise Value for the quarter that ended in Dec. 2023 was $-1,778.9 Mil. Galapagos NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $6.7 Mil. Galapagos NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -0.38%.


Galapagos NV EV-to-EBIT Historical Data

The historical data trend for Galapagos NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Galapagos NV Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.09 -0.44 13.45 21.88 -167.33

Galapagos NV Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.88 53.09 -687.14 -317.94 -167.33

Competitive Comparison

For the Biotechnology subindustry, Galapagos NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galapagos NV EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Galapagos NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Galapagos NV's EV-to-EBIT falls into.



Galapagos NV EV-to-EBIT Calculation

Galapagos NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-2005.046/6.741
=-297.44

Galapagos NV's current Enterprise Value is $-2,005.0 Mil.
Galapagos NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV  (OTCPK:GLPGF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Galapagos NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=6.741/-1778.890078
=-0.38 %

Galapagos NV's Enterprise Value for the quarter that ended in Dec. 2023 was $-1,778.9 Mil.
Galapagos NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Galapagos NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Galapagos NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Galapagos NV (Galapagos NV) Business Description

Address
Generaal De Wittelaan L11 A3, Mechelen, BEL, 2800
Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.